首站-论文投稿智能助手
典型文献
Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia:a multi-centric randomized clinical trial
文献摘要:
We aimed to evaluate the effectiveness and safety of single-course initial regimens in patients with low-risk gestational trophoblastic neoplasia(GTN).In this trial(NCT01823315),276 patients were analyzed.Patients were allocated to three initiated regimens:single-course methotrexate(MTX),single-course MTX+dactinomycin(ACTD),and multi-course MTX(control arm).The primary endpoint was the complete remission(CR)rate by initial drug(s).The primary CR rate was 64.4%with multi-course MTX in the control arm.For the single-course MTX arm,the CR rate was 35.8%by one course;it increased to 59.3%after subsequent multi-course MTX,with non-inferiority to the control(difference-5.1%,95%confidence interval(CI)-19.4%to 9.2%,P=0.014).After further treatment with multi-course ACTD,the CR rate(93.3%)was similar to that of the control(95.2%,P=0.577).For the single-course MTX+ACTD arm,the CR rate was 46.7%by one course,which increased to 89.1%after subsequent multi-course,with non-inferiority(difference 24.7%,95%CI 12.8%-36.6%,P<0.001)to the control.It was similar to the CR rate by MTX and further ACTD in the control arm(89.1%vs.95.2%,P=0.135).Four patients experienced recurrence,with no death,during the 2-year follow-up.We demonstrated that chemotherapy initiation with single-course MTX may be an alternative regimen for patients with low-risk GTN.
文献关键词:
作者姓名:
Lili Chen;Ling Xi;Jie Jiang;Rutie Yin;Pengpeng Qu;Xiuqin Li;Xiaoyun Wan;Yaxia Chen;Dongxiao Hu;Yuyan Mao;Zimin Pan;Xiaodong Cheng;Xinyu Wang;Qingli Li;Danhui Weng;Xi Zhang;Hong Zhang;Quanhong Ping;Xiaomei Liu;Xing Xie;Beihua Kong;Ding Ma;Weiguo Lu
作者机构:
Department of Gynecological Oncology,Women's Hospital,Zhejiang University School of Medicine,Hangzhou 310006,China;Department of Obstetrics and Gynecology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Department of Obstetrics and Gynecology,Qilu Hospital of Shandong University,Jinan 250012,China;Department of Obstetrics and Gynecology,West China Second University Hospital of Sichuan University,Chengdu 610041,China;Key Laboratory of Birth Defects and Related Disease of Women and Children(Sichuan University),Ministry of Education,Chengdu 610041,China;Tianjin Central Hospital of Gynecology Obstetrics,Tianjin 300052,China;Shengjing Hospital of China Medical University,Shenyang 110021,China
文献出处:
引用格式:
[1]Lili Chen;Ling Xi;Jie Jiang;Rutie Yin;Pengpeng Qu;Xiuqin Li;Xiaoyun Wan;Yaxia Chen;Dongxiao Hu;Yuyan Mao;Zimin Pan;Xiaodong Cheng;Xinyu Wang;Qingli Li;Danhui Weng;Xi Zhang;Hong Zhang;Quanhong Ping;Xiaomei Liu;Xing Xie;Beihua Kong;Ding Ma;Weiguo Lu-.Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia:a multi-centric randomized clinical trial)[J].医学前沿,2022(02):276-284
A类:
dactinomycin,NCT01823315,MTX+dactinomycin,ACTD,MTX+ACTD
B类:
Chemotherapy,initiation,single,course,methotrexate,alone,combined,versus,multi,risk,gestational,trophoblastic,neoplasia,centric,randomized,clinical,trial,We,aimed,evaluate,effectiveness,safety,initial,regimens,patients,GTN,In,this,were,analyzed,Patients,allocated,three,initiated,control,arm,primary,endpoint,was,complete,remission,CR,by,drug,For,increased,after,subsequent,inferiority,difference,confidence,interval,After,further,treatment,similar,that,which,It,Four,experienced,recurrence,death,during,year,follow,up,demonstrated,chemotherapy,may,be,alternative
AB值:
0.355019
相似文献
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Ming Bai;Meng Wang;Ting Deng;Yuxian Bai;Kai Zang;Zhanhui Miao;Wenlin Gai;Liangzhi Xie;Yi Ba-Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin 300060,China;Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Medical Oncology,Henan Cancer Hospital,The Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China;Oncology Department,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China;Sinocelltech Ltd.,Beijing 100176,China;Beijing Engineering Research Center of Protein and Antibody,Beijing 100176,China;Cell Culture Engineering Center,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100176,China
Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression?A systematic review and meta-analysis
Ming-min Xu;Pei Guo;Qing-yu Ma;Xuan Zhou;Yu-long Wei;Lu Wang;Yue Chen;Yu Guo-School of Traditional Chinese Medicine,Jinan University,Guangzhou 510632,Guangdong Province,China;Acupuncture and Tuina School/Third Teaching Hospital,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;School of Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;Guangzhou Key Laboratory of Formula-Pattern of Traditional Chinese Medicine,Formula-Pattern Research Center,Jinan University,Guangzhou 510632,Guangdong Province,China;School of Acupuncture-Moxibustion and Tuina,Beijing University of Chinese Medicine,Beijing 100029,China
Safety and efficacy of ciprofol vs. propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial
Liu Yongjun;Yu Xiangyou;Zhu Duming;Zeng Jun;Lin Qinhan;Zang Bin;Chen Chuanxi;Liu Ning;Liu Xiao;Gao Wei;Guan Xiangdong-Department of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China;Department of Critical Care Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China;Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China;Department of Critical Care Medicine, Guangzhou First People’s Hospital, Guangzhou 510180, China;Department of Critical Care Medicine, Qingyuan People’s Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan 511518, China;Department of Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang 110022, China;Department of Research and Development, Haisco Pharmaceutical Group Co., Ltd, Shanghai 201203, China
Efficacy and safety of high-dose esomeprazole–amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial
Bi Hanxin;Chen Xingxing;Chen Yuxin;Zhao Xin;Wang Shasha;Wang Jiehong;Lyu Ting;Han Shuang;Lin Tao;Li Mingquan;Yuan Donghong;Liu Junye;Shi Yongquan-Xi’an Medical University, Xi’an, Shaanxi 710021, China;State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi 710032, China;Department of Gastroenterology, Xianyang Central Hospital, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Shaanxi Nuclear Industry 215 Hospital, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Xi’an Red Cross Hospital, Xi’an, Shaanxi 710054, China;Department of Gastroenterology, Xi’an Daxing Hospital, Xi’an, Shaanxi 710082, China;Department of Gastroenterology, Yan’an People’s Hospital, Yan’an, Shaanxi 716000, China;Department of Gastroenterology, Yan’an University Affiliated Hospital, Yan’an, Shaanxi 716000, China;Department of Radiation Protective Medicine, Air Force Medical University, Xi’an, Shaanxi 710032, China
Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study
Zhu Huiyun;Pan Xue;Zhang Li;Sun Hongxin;Fan Huizhen;Pan Zhongwei;Huang Caibin;Shi Zhenwang;Ding Jin;Wang Qi;Du Yiqi;Lyu Nonghua;Li Zhaoshen-Department of Gastroenterology, Changhai Hospital of Navy Military Medical University, Shanghai 200433, China;Drug Clinical Trial Institution, Changhai Hospital of Navy Military Medical University, Shanghai 200433, China;Department of Gastroenterology, Yichun People’s Hospital, Yichun, Jiangxi 336028, China;Department of Gastroenterology, Meihekou Central Hospital, Meihekou, Jilin 135099, China;Department of Gastroenterology, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi 341001, China;Department of Gastroenterology, Hefei Second People’s Hospital, Hefei, Anhui 230011, China;Department of Gastroenterology, Jinhua Central Hospital, Jinhua, Zhejiang 321099, China;Department of Gastroenterology, Anqing Municipal Hospital, Anqing, Anhui 246004, China;Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China
Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial
Liu Bicheng;Chen Nan;Zhao Jinghong;Yin Aiping;Wu Xiongfei;Xing Changying;Jiang Gengru;Fu Junzhou;Wang Mei;Wang Rong;Niu Jianying;Fu Ping;Ni Zhaohui;Hou Fanfan;Zhao Jiuyang;Chen Jing;Chen Yuqing;Shi Wei;Chen Jianghua;Li Wenge;Xu Gang;Zhong Ling;Liu Wenhu;Ding Guohua;Kondo Yuichiro;Yue Changhe;Mei Changlin-Department of Nephrology, Zhongda Hospital Southeast University, Nanjing, Jiangsu 210009, China;Department of Nephrology, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;Department of Nephrology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China;Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China;Department of Nephrology, Southwest Hospital of Army Medical University, Chongqing 400039, China;Department of Nephrology, Jiangsu Provincial Hospital, Nanjing, Jiangsu 210036, China;Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;Department of Nephrology, Guangzhou First People's Hospital, Guangzhou, Guangdong 510180, China;Department of Nephrology, Peking University People's Hospital, Beijing 100044, China;Department of Nephrology, Shandong Provincial Hospital, Jinan, Shandong 250021, China;Department of Nephrology, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China;Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Nephrology, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200001, China;Department of Nephrology, Nanfang Hospital Southern Medical University, Guangzhou, Guangdong 510510, China;Department of Nephrology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, China;Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200040, China;Department of Nephrology, Peking University First Hospital, Beijing 100034, China;Department of Nephrology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, China;Department of Nephrology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China;Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China;Department of Nephrology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China;Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China;R&D Planning Department, R&D Division, Kyowa Kirin Co., Ltd., Tokyo 520-5292, Japan;D&R Office, Kyowa Kirin China Pharmaceutical Co., Ltd., Shanghai 201203, China;Department of Nephrology, Shanghai Changzheng Hospital, Shanghai 200003, China
A multi-center, open-label, randomized, parallel-controlled phase Ⅱ study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera?) in patients with CD20-positive B-cell non-Hodgkin lymphoma
Xiaohong Han;Mingzhi Zhang;Huaqing Wang;Qingyuan Zhang;Wei Li;Miaowang Hao;Yuhuan Gao;Jie Jin;Hanyun Ren;Yun Tang;Xiaonan Hong;Xiaoyan Ke;Hang Su;Lin Gui;Jianmin Luo;Liangzhi Xie;Wenlin Gai;Yuankai Shi-Clinical Pharmacology Research Center,Peking Union Medical College Hospital,State Key Laboratory of Complex Severe and Rare Diseases,NMPA Key Laboratory for Clinical Research and Evaluation of Drug,Beijing Key Laboratory of Clinical PK&PD Investigation for Innovative Drugs,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Medical Oncology,Tianjin People's Hospital,Tianjin 300121,China;Department of Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Oncology Department of Cancer Center,the First Hospital of Jilin University,Changchun 130021,China;Department of Hematology,Tangdu Hospital,Air Force Medical University,Xi'an 710038,China;Department of Hematology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Hematology,the First Affiliated Hospital of Zhejiang University,Hangzhou 310003,China;Department of Hematology,Peking University First Hospital,Beijing 100034,China;Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Medical Oncology,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Lymphoma,the Fifth Medical Center of PLA General Hospital,Beijing 100071,China;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China;Department of Hematology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;Beijing Engineering Research Center of Protein and Antibody,Sinocelltech Ltd.,Beijing 100176,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。